These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 4692997)
1. Tetracycline inequivalence: the importance of 96-hour testing. Davis CM; Vandersarl JV; Kraus EW Am J Med Sci; 1973 Jan; 265(1):69-74. PubMed ID: 4692997 [No Abstract] [Full Text] [Related]
2. Cross-over study of ten tetracycline preparations. Tuomisto J; Männistö P Eur J Clin Pharmacol; 1973 Jun; 6(1):64-8. PubMed ID: 4587517 [No Abstract] [Full Text] [Related]
4. [Differentiation of the degree of bioavailability of peroral drug forms of tetracycline hydrochloride in experiments on laboratory animals]. Zak AF; Ermolova OB Antibiotiki; 1976 Feb; 21(2):151-5. PubMed ID: 1275466 [TBL] [Abstract][Full Text] [Related]
5. Biological availability and in vitro release from oral oxytetracycline and tetracycline preparations. Bergan T; Oydvin B; Lunde I Acta Pharmacol Toxicol (Copenh); 1973; 33(2):138-56. PubMed ID: 4585587 [No Abstract] [Full Text] [Related]
9. Inhibitory effect of various iron salts on the absorption of tetracycline in man. Neuvonen PJ; Turakka H Eur J Clin Pharmacol; 1974 Aug; 7(5):357-60. PubMed ID: 4213690 [No Abstract] [Full Text] [Related]
10. [The passage of pyrrolidinomethyltetracycline (PMT) into the aqueous humor of man after systemic administration]. Moog E; Knothe H; Vogel F; Fabricius K Klin Monbl Augenheilkd; 1969 Dec; 155(6):828-36. PubMed ID: 5365971 [No Abstract] [Full Text] [Related]
11. Evaluation of the clinical inequivalency of drug products of varying bioavailability. Barr WH; Adir J Ann Clin Res; 1974; 6(0):suppl 11:48-56. PubMed ID: 4605465 [No Abstract] [Full Text] [Related]
12. A disintegration test for evaluation of drug availability from tablets and capsules. Sandell E; Eriksson K; Mellström G Acta Pharm Suec; 1970 Nov; 7(5):559-66. PubMed ID: 5275191 [No Abstract] [Full Text] [Related]
13. [Use of some compounds of the tetracycline series in patients with chronic renal insufficiency]. Iarmolinskiĭ IS; Vasina TA; Navolotskaia TI; Goriaĭnov VA; Butylina LV Antibiotiki; 1970 Dec; 15(12):1125-8. PubMed ID: 4925643 [No Abstract] [Full Text] [Related]
14. [Pathogenesis of infectious and drug allergy in patients with acute dysentery and their relationship to the method of tetracycline administration]. Klimov KV; Riazanova NIa Antibiotiki; 1971 Feb; 16(2):145-9. PubMed ID: 4397622 [No Abstract] [Full Text] [Related]
15. [Rate of tetracycline dissolution from tablets and capsules and the biological availability of the antibiotic]. Okhotnikova VF; Grakovskaia LK; Koroleva VG; Minasova GS; Zak IR Antibiotiki; 1976 Aug; 21(8):719-21. PubMed ID: 999252 [TBL] [Abstract][Full Text] [Related]
18. [Application of triple tetracycline in internal medicine]. Sugino S Jpn J Antibiot; 1968 Aug; 21(4):192-6. PubMed ID: 4974352 [No Abstract] [Full Text] [Related]
19. Effects of blood levels of tetracycline and oxytetracycline on hepatic and renal functions in normal subjects. Taneja OP; Grover NK; Thakur LC; Bhatia VN Chemotherapy; 1974; 20(4):201-11. PubMed ID: 4413117 [No Abstract] [Full Text] [Related]
20. [The consequence of the preparation factors for the effect of the drug]. Johnsgård M; Pedersen AO Tidsskr Nor Laegeforen; 1973 Apr; 93(10):698-703. PubMed ID: 4755086 [No Abstract] [Full Text] [Related] [Next] [New Search]